1 / 12

Myocardial Ischemia Redefined: Optimal Care in CAD

Myocardial Ischemia Redefined: Optimal Care in CAD. Learning objectives. To improve patient management through a better understanding of:. Pathophysiology of myocardial ischemia Efficacy and safety of behavioral and pharmacologic approaches to minimize recurring ischemic episodes

tait
Download Presentation

Myocardial Ischemia Redefined: Optimal Care in CAD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Myocardial Ischemia Redefined:Optimal Care in CAD

  2. Learning objectives To improve patient management through a better understanding of: • Pathophysiology of myocardial ischemia • Efficacy and safety of behavioral and pharmacologic approaches to minimize recurring ischemic episodes • Clinical trials investigating multiple treatment targets • Current clinical guidelines

  3. Curriculum overview • Epidemiology and prevalence of myocardial ischemia • Magnitude of the problem • Challenges in selected populations • Issues in contemporary clinical practice • Scientific review • Clinical trial update • New guidelines in myocardial ischemia management • Risk stratification

  4. Chronic ischemic heart disease: Overview • Highly prevalent • 6.5-16.5 million in the US • Multifactorial etiology • CAD, hypertension, hypertrophic cardiomyopathy, valvular heart disease • High socioeconomic burden • Depression • ↓Quality of life • High costs of care Gibbons RJ et al. www.acc.org.

  5. Repeat revascularization is common post-PCI/CABG N = 18,240 who underwent elective PCI or CABG 50 46 40 30 30 Patients(%) 20 10 0 Recurrentangina 2nd revascularization Kempf J et al. Presented at ESC. 2007.

  6. Angina increases cost of care US managed care enrollees, n = 140,001 with asymptomatic CAD, n = 23,535 with angina Dx* Average yearly cost/patient $11,530 (asymptomatic CAD) vs $22,004 (angina) ED visits ED visits Hospitalizations Prior to diagnosis Following diagnosis Kempf J et al. Presented at Scientific Forum on Quality of Care and Outcomes Res in CV Disease. 2006. *And Rx nitrates and/or β-blockers and/or CCBs

  7. Challenges in selected populations: Pathophysiology and implications of ischemic heart disease in women Women Ischemic heart disease Diabetes Elderly

  8. WISE: Landmark study in women Prospective cohort study conducted at 4 US sites Goals: • Improve diagnostic testing for ischemic heart disease in women • Study pathophysiologic mechanisms for ischemia in the absence of epicardial coronary artery stenoses • Evaluate the influence of menopausal status and reproductive hormone levels on diagnostic testing results Women’s Ischemia Syndrome Evaluation Bairey Merz CN et al. J Am Coll Cardiol. 1999;33:1453-61.

  9. WISE: Persistent chest pain in women predicts future CV events n = 673 WISE participants with chest pain at baseline 1 0.9 Without CAD HR 1.89 (1.06–3.39)P = 0.03 Event-freesurvival (%) 0.8 0.7 With CAD HR 1.17 (0.76–1.80)P = 0.49 0.6 0 1 2 3 4 5 6 Years from PChP diagnosis (at one year) Neither PChPNo CAD No PChPCAD Both PChP = persistent chest pain Johnson BD et al. Eur Heart J. 2006;27:1408-15.

  10. WISE: Persistent chest pain associated with diminished QOL *Adjusted P ≤ 0.04 †Range: 1 - 10 (best); ‡score = trait Johnson BD et al. Eur Heart J. 2006;27:1408-15. Bairey Merz CN et al. J Am Coll Cardiol. 1999;33:1453-61.

  11. WISE: CAD imposes an economic burden N = 883 women with angiographic CAD 80 70 * * * 60 * 50 Cumulative observed direct costs ($, thousands) 40 * 30 20 10 0 1 2 3 4 5 Follow-up (years) Nonobstructive CAD 1 vessel CAD 2 vessel CAD 3 vessel CAD *P < 0.0001 nonobstructive vs 1-3 vessel CAD Shaw LJ et al. Circulation. 2006;114:894-904.

  12. Contemporary clinical practice of ischemic heart disease Opportunity for early detection, risk stratification, and medical therapy Healthy population Revas = revascularization Adapted from Timmis AD et al. Heart. 2007;93:786-91.

More Related